Practices for ordering kidney biopsies or prescribing glucocorticoids for patients with immunoglobulin A nephropathy vary among physicians in Canada, according to study data published in Kidney360.
Researchers wrote that understanding variability patterns for physicians treating patients with immunoglobulin A (IgA) nephropathy could help inform treatment strategies and improve adoption of updated Kidney Disease: Improving Global Outcomes guidelines.
“Understanding preexisting physician practice patterns is critical for interpreting the uptake of emerging evidence and increasing

More than half of patients with treatment-resistant hidradenitis suppurativa achieved a 55% improvement in their disease after initiating golimumab, a tumor necrosis factor inhibitor, according to a study published in JAMA Dermatology.
Tumor necrosis factor (TNF) inhibitors are often used to treat HS; however, clinicians have only one FDA-approved TNF inhibitor for this indication, adalimumab (Humira, AbbVie), though many also use infliximab (Zymfentra, Celltrion) off-label, Christopher J. Sayed, MD, professor of dermatology at the University of North Carolina at Chapel Hill, and Madeline

The association between traumatic brain injuries and certain neurological diseases could go in both directions, according to research published in Neurology.
The study, conducted by researchers with the San Francisco Veterans Affairs Health Care System in California, showed older veterans with a recent traumatic brain injury (TBI) were three times more likely to have had a prior diagnosis of a stroke, dementia or Parkinson’s disease, and were four times more likely to have had a prior diagnosis of epilepsy, the authors wrote.
“The main takeaway from this study is that fall prevention is

PHILADELPHIA — Body composition and obesity-related complications differ between men and women, but incretin-based medications confer benefits among all adults, according to a speaker at the Heart in Diabetes CME Conference.
Samuel Klein, MD, division chief of nutritional science and obesity medicine at Washington University in St. Louis, outlined some of the biggest differences in how obesity presents itself among women compared with men and discussed some of the key risk factors health care professionals need to be aware of when managing obesity. Despite the differences between the sexes,

Machine learning models that use electronic health record data to predict obstructive sleep apnea had greater performance than two screening questionnaires, according to a poster presented at SLEEP 2026 Annual Meeting.
“Because these models rely solely on pre-existing EHR data, the prediction output can run passively in the background for any given patient,” Nathanael H. Hwang, research intern at Beth Israel Deaconess Medical Center, told Healio. “An OSA risk profile can therefore be generated for each patient and made available for clinicians to review in the course of their care.
“This

More adults with chronic inducible urticaria receiving remibrutinib vs. placebo achieved complete symptom control at week 12, according to data presented at the 2026 European Academy of Allergy and Clinical Immunology Annual Congress.
“When second-generation H1-antihistamines alone do not provide relief, patients with chronic inducible urticaria (CIndU) may have the option to add on Rhapsido,” Giselle Mosnaim, MD, allergist and immunologist at Endeavor Health, told Healio.
In the global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 RemIND study, Mosnaim and

When a patient with cancer tells their clinician they smoke, Andrea C. King, PhD, wants alarm bells to ring inside the exam room — figuratively speaking.
“Helping patients to quit smoking should be a standard of care,” King, professor of psychiatry and behavioral neuroscience at The University of Chicago, told Healio.
The No Smoker Left Behind initiative at The University of Chicago Comprehensive Cancer Center aims to make that a reality.
The opt-out program proactively reaches out to all patients with cancer listed as current smokers in the electronic health record (EHR) and subsequently offers

The FDA has declined to approve Sobi’s investigational infusion of nanoencapsulated sirolimus plus pegadricase for adults with uncontrolled gout, according to a press release from the manufacturer.
The FDA issued a complete response letter to Sobi requiring additional information regarding manufacturing control strategy of the biological component of the drug, as well as to address contract manufacturing facility deficiencies, the press release stated.
According to Sobi, the FDA has “identified no concerns regarding the clinical efficacy or safety” of nanoencapsulated